A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

NCT01292473 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

323

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Idiopathic Urticaria

Interventions

DRUG: Placebo
DRUG: Omalizumab

Sponsor

Genentech, Inc.